首页> 外文OA文献 >Prognostic impact offibroblast growth factor receptor 2gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers

【2h】

Prognostic impact offibroblast growth factor receptor 2gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers

机译：预后抗冲流细胞增生因子受体2基因扩增含氟嘧啶和铂化疗转移和局部先进的不可切除胃癌

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Seyoung Seo; Seong Joon Park; Min-Hee Ryu; Sook Ryun Park; Baek-Yeol Ryoo; Young Soo Park; Young-Soon Na; Chae-Won Lee; Ju-Kyung Lee; Yoon-Koo Kang;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Clinical significance of MET gene amplification in metastatic or locally advanced gastric cancer treated with first-line fluoropyrimidine and platinum combination chemotherapy [J] . Seyoung Seo, Min-Hee Ryu, Baek-Yeol Ryoo, 中国癌症研究（英文版） . 2019,第004期

机译：一线氟嘧啶和铂联合化疗治疗转移性或局部晚期胃癌MET基因扩增的临床意义
2. BOLERO-4: A PHASE 2, OPEN-LABEL, MULTICENTER, SINGLE-ARM TRIAL INVESTIGATING THE EFFICACY AND SAFETY OF FIRST-LINE EVEROLIMUS (EVE) IN COMBINATION WITH LETROZOLE (LET) IN POSTMENOPAUSAL PATIENTS (PTS) WITH ESTROGEN RECEPTORPOSITIVE (ER plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) METASTATIC OR LOCALLY ADVANCED UNRESECTABLE BREAST CANCER (BC) [J] . Bachelot Thomas, Villanueva Cristian, Royce Melanie, The Breast : . 2015,第Suppla3期

机译：BOLERO-4：第2阶段，开放式，多中心，单臂试验，研究了绝经后患者（PTS）和雌激素受体阳性（ER + ），人类表皮生长因子受体2-阴性（HER2-）转移性或局部晚期无法治疗的乳腺癌（BC）
3. BOLERO-4: A PHASE 2, OPEN-LABEL, MULTICENTER, SINGLE-ARM TRIAL INVESTIGATING THE EFFICACY AND SAFETY OF FIRST-LINE EVEROLIMUS (EVE) IN COMBINATION WITH LETROZOLE (LET) IN POSTMENOPAUSAL PATIENTS (PTS) WITH ESTROGEN RECEPTORPOSITIVE (ER plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) METASTATIC OR LOCALLY ADVANCED UNRESECTABLE BREAST CANCER (BC) [J] . Bachelot Thomas, Villanueva Cristian, Royce Melanie, The Breast : . 2015,第Suppla3期

机译：Bolero-4：第2阶段，开放标签，多中心，单手臂试验研究一线血酮（前夕）与雌激素受体展（PTS）在绝经后患者（PTS）中的Letrozole（Let）的疗效和安全性（ER Plus ），人表皮生长因子受体2阴性（HER2-）转移性或局部先进的不可切除的乳腺癌（BC）
4. Weekly Paclitaxel Therapy as the Second-line Chemotherapy to TS-1 for Advanced/Metastatic Gastric Cancer [C] . M. Fujishima, H. Imamura, H. Furukawa, International Gastric Cancer Congress . 2005

机译：每周紫杉醇治疗作为先进/转移性胃癌的二线化学疗法至TS-1
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers [O] . Seyoung Seo, Seong Joon Park, Min-Hee Ryu, 2017

机译：成纤维细胞生长因子受体2基因扩增对接受氟嘧啶和铂类化学疗法治疗的转移性和局部晚期不可切除胃癌患者的预后影响
7. The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer [O] . Atmaca, Akin, Werner, Dominique, Pauligk, Claudia, 2012

机译：表皮生长因子受体对转移性胃癌患者的预后影响

Prognostic impact offibroblast growth factor receptor 2gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers

著录项

相似文献

相关主题

期刊订阅